Cytokine Storm Therapy Market Overview
Cytokine storm therapy is the treatment for hypercytokinemia or the maladaptive release of cytokines induced by infections, autoimmune diseases and immune dysregulations.
According to the World Health Organization (WHO), chronic inflammatory diseases are the most significant ailment claiming lives globally, with 125 million affected in the U.S. and 61 million affected with multiple chronic inflammatory diseases. The recent emergence of Coronavirus has infected 19,687,156 and 727,435 deaths globally, stated by WHO. The symptoms are diagnosed with fever, inflammations, severe exhaustiveness and nausea.
Cytokines including interleukins, interferons and chemokines are released in high concentrations after the exaggerated immune response by the dysregulated T-cell activation, macrophages and differentiation into regulatory T-cells. Cytokine storm therapy includes immunomodulatory, plasma, stem-cell therapy and cytokine absorption devices.
The global cytokine storm therapy market is poised to grow lucratively rate with the surging viral diseases, inflammatory disease such as pancreatitis, autoimmune diseases such as multiple sclerosis, sepsis and others, coupled with the escalating research, clinical developments and healthcare expenditures. Coronavirus or COVID-19 pandemic has boosted the global cytokine storm therapy market, with the rigorous research, drug production and diagnostics of the cytokine storm.
Cytokine Storm Therapy Market: Drivers and Restraints
The drivers of the global cytokine storm therapy market include the increasing viral diseases such as COVID-19, Influenza, Ebola, autoimmune and inflammatory diseases causing cytokine storm. Also, the massive demand for therapeutics propels the research investments, along with advancement of global healthcare infrastructure and expenditures.
Governments’ supportive policies, reimbursements and subsidized drugs also fuel the market. Drug manufacturers are dwelling with the key motive of developing novel, effective and safer cytokine storm therapies.
Sales of several drugs have surged including Intravenous Immunoglobulins (IVIG) Tocilizumab, Tissue necrosis factor (TNF) blocker, Anakinra, Interleukin Antagonists, Anti-inflammatory drugs such as Corticosteroids and other NSAIDs, Chloroquine, Ulinastatin and Hydroxychloroquine.
Also, Cytokine absorption devices to absorb excessive concentration of cytokines, stem-cell therapy by using mesenchymal stem cells (MSC) are being implemented to curb the abnormal activation of T-cells and macrophages.
However, global cytokine storm therapy market is constrained by the adverse reactions and limited availability of cytokine storm drugs. Further research is required for understanding the science of the cytokine storm and disease pathogenesis.
Although, the surging cases of cytokine storm, active clinical development of cytokine storm therapies, and rigorous researches are unraveling scientific information of disease development propelling the drug development processes, and rocketing the growth of global cytokine storm therapy market.
Cytokine Storm Therapy Market: Overview
The global cytokine storm therapy market is growing lucratively due to the surging diseases, active research, healthcare expenditures and clinical trials. By diseases, viral diseases lead the cytokine storm therapy market. Recent global pandemic, COVID-19 has propelled the research and clinical development activities in cytokine storm therapy market wit fast paced R&D and approvals for cytokine storm therapy.
By treatment, Immunomodulatory therapy dominates the treatment segment of the cytokine storm therapy market. COVID 19, influenza and other viral infections marked with the cytokine storm have claimed millions of deaths globally and pushing the research, healthcare and drug development activities to develop therapy such as Tocilizumab, Chloroquine and Hydroxychloroquine to curb the massive infections and deaths.
By distribution channels, hospital pharmacies dominates the cytokine storm therapy distribution due to the advanced medical infrastructure and expenditures, along with the trained medical staff for treatment, prescriptions, government reimbursements and other supportive policies.
Cytokine Storm Therapy Market: Regional Outlook
North America dominates the global cytokine storm therapy market, wherein the U.S. leads the region with its rigorous research activities for fast-paced drug development for cytokine storm associated with viral diseases. The healthcare infrastructure, key market players, governments’ support and partnership with companies to meet the unprecedented demands of therapeutics propels the cytokine storm therapy market.
Europe holds a significant global market of cytokine storm therapy driven by the sophisticated research, medical protocols and healthcare expenditure, with contributing states such as France, Italy and Germany.
Asia pacific cytokine storm therapy market is growing at the fastest pace, fuelled by China, India and Japan, with their active research institutes, clinical trials and drug manufacturers-government collaborations for faster drug development and approvals.
China leads the cytokine storm therapy research, for being a major supplier of active pharmaceutical ingredients and advancing drug developments. Latin America cytokine storm therapy market is growing gradually with the research and rising therapeutics demands.
MEA and South-Africa cytokine storm therapy market is experiencing a stagnant cytokine storm therapy market growth, although, with the advancing research and healthcare of Israel and South-Africa, the future growth of market is expected.
Cytokine Storm Therapy Market: Key Players
The key players of global cytokine storm therapy market include
- Gilead Sciences
- Johnson & Johnson
- Regeneron Pharmaceuticals Biocon
- Quotient Sciences
- Acerta Pharma and Sun Pharma.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Poland, Russia)
- Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Cytokine Storm Therapy Market: Segmentation
The global cytokine storm therapy market is segmented into diseases, treatments, distribution channels and regions
- Viral (COVID 19, Influenza, Dengue, Ebola)
- Multiple sclerosis
- Immunomodulatory therapy (Anti-inflammatory drugs, Biological/ chemical modifiers, Immunoglobin therapy)
- Plasma therapy
- Stem-cell therapy
- Cytokine absorption devices (extracorporeal membrane oxygenation (ECMO))
- Hospitals pharmacies
- Retailer pharmacies
- Online pharmacies